Metastatic jejunal VIPoma: Beneficial effect of combination therapy with interferon-α and 5-fluorouracil

American Journal of Gastroenterology

Volumn 95, Issue 1, 2000, Pages 289-293

  Cellier, Christophe ^a   Yaghi, César ^a   Cuillerier, Emmanuel ^a   Siauve, Nathalie ^a   Berger, Anne ^a   Carnot, Françoise ^a   Haddad, Charles ^a   Barbier, Jean Philippe ^a   Landi, Bruno ^a  

^a Hopital Laennec   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; DRUG EFFICACY; HUMAN; JEJUNUM CANCER; MALE; METASTASIS; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; TUMOR REGRESSION; VIPOMA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLUOROURACIL; HUMANS; INTERFERON-ALPHA; JEJUNAL NEOPLASMS; LIVER NEOPLASMS; MALE; PERITONEAL NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; VIPOMA;

EID: 0033988976     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(99)00770-4     Document Type: Article

References (28)

1. Mekhjian H.S., O'Dorisio T.M. VIPoma syndrome. Semin Oncol. 14:1987;282.
2. Verner J.V., Morrison A.B. Islet-cell tumor and a syndrome of refractory watery diarrhea and hypokaliemia. Am J Med. 25:1958;374-380.
3. Capella C., Polak J.M., Buffa R., et al. Morphologic patterns and diagnostic criteria of VIP producing endocrine tumors. Cancer. 52:1983;1860-1874.
4. Long R.G., Bryant M.G., Mitchell S.J., et al. Clinicopathological study of pancreatic and ganglioneuroblastoma tumors secreting vasoactive intestinal peptide. Br Med J. 282:1981;1767.
5. Eriksson B., Oberg K., Alm G., et al. Treatment of malignant endocrine pancreatic tumors with human leucocyte interferon. Lancet. 1986;1307-1309.
6. Engstrom P.F., Lavin P.T., Moertel C.G., et al. Streptozotocin plus fluorouracil vs doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol. 2:1984;1255-1259.
7. Moertel C.G., Lavin P., Hahn G. Phase II trial doxorubicin therapy for advanced islet cell carcinoma. Cancer Treat Rep. 66:1982;1567-1569.
8. Moertel C.G., Hanley J.A., Johnson L.A. Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet cell carcinoma. N Engl J Med. 303:1980;1189-1194.
9. Moertel C.G., Lefkopoulo M., Lipstiz S., et al. Streptozotocin-doxorubicin, streptozotocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 326:1992;519-523.
10. Oberg K., Eriksson B. Medical treatment of neuroendocrine gut and pancreatic tumors. Acta Oncol. 28:1989;425.
11. Moertel C.G., Kvols L.K., O'Connell M.J., et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer. 68:1991;227-232.
12. Reubi J.C. Somatostatin receptors in health and disease the molecular basis for in vivo imaging . J Nucl Med. 36:1995;1825-1835.
13. Lamberts S.W., Van der Lely A.J., De Herder W.W., et al. Octreotide. N Engl J Med. 334:1996;246-254.
14. Kubota A., Yamada Y., Ragimoto S., et al. Identification of somatostatin analogue SMS 201-995 in the treatment of neuroendocrine tumors. J Clin Invest. 93:1994;1321-1325.
15. Blanchin M., James-Deider A., Chaumet-Riffaud P.D., et al. Utilisation de l'octreotide dans les tumeurs endocrines digestives. Etude française multicentrique. Presse Med. 21:1992;697-702.
16. Wood S.M., Kraenzlin M.E., Adrian T.E., et al. Treatment of patients with pancreatic tumors using a new long standing somatostatin analogue Symptomatic and peptide response . Gut. 26:1985;438-444.
17. Glenn D., Camp R.C., Raskin P., et al. Somatostatin enhances water and sodium absorption. Gastroenterology. 78:1980;346-349.
18. Maton P.N., O'Dorisio T.M., O'Dorisio M.S., et al. Successful therapy of pancreatic cholera with long acting somatostatin analogue SMS 201-995. Scand J Gastroenterol. 119:1986;181.
19. Kraenzlin M.E., Chang J.L., Wood S.M., et al. Long term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology. 88:1985;185-187.
20. Saltz L., Trochanowski B., Buckley M., et al. Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumors. Cancer. 72:1993;244-248.
21. Ruszniewski Blumberg J., Cloarec D., et al. Treatment of the car- cinoid syndrome with the long lactin somatostatin analogue lan- reotide A prospective study in 39 patients . Gut. 39:1996;279-283.
22. Dirix L.Y., Vermeulen P.B., Fierens H., et al. Long-term results of continuous treatment with recombinant interferon alpha in patients with metastatic carcinoid - An antiangiogenic effect? Anti-Cancer Drugs. 7:1996;175-181.
23. Oberg K. Neuroendocrine gastrointestinal tumors. Ann Oncol. 7:1996;453-463.
24. Bajetta E., Zilembo N., Di Bartolomeo M., et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon alpha-2a. A study by the Italian Trials in Medical Oncology Group. Cancer. 72:1993;3099-3105.
25. Andreyev H.J.N., Scott-Mackie P., Cuningham D., et al. Phase II study of continuous infusion fluorouracil, and interferon alpha-2b in the palliation of malignant neuroendocrine tumors. J Clin Oncol. 13:1995;1486-1492.
26. Alghen J.D., Leming P.D., Gullo J.J., et al. Protracted infusional 5-FU + alpha2b-interferon in metastatic carcinoid. Updated experience with Mid-Atlantic Oncology Program. J Clin Oncol. 13:1995;552A. (abstract).
27. Hughes M.J., Kerr D.J., Cassidy J., et al. A pilot study of combination therapy with interferon-alpha-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumors. Ann Oncol. 7:1996;208-210.
28. Rosewicz S., Weder M., Kaiser A., et al. Antiproliferative effects of interferon alpha on human pancreatic carcinoma cell lines are associated with differential regulation of protein kinase C isoenzymes. Gut. 39:1996;255-261.